Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $38.06
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 23, 26 |
Daily · Wilder smoothing
| Barclays |
| maintain |
| Overweight |
| Overweight |
| Oct 1, 26 | Truist Securities | maintain | Buy | Buy |
| Sep 25, 26 | Raymond James | maintain | Outperform | Outperform |
| Jul 30, 26 | Citizens | maintain | Market Outperform | Market Outperform |
| Jul 30, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Jul 30, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 29, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 29, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Apr 29, 26 | Wells Fargo | maintain | Overweight | Overweight |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 46.42 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 65.39 | Oscillator | Neutral |
| Williams %R (14) | -6.40 | Oscillator | Sell |
| MACD (12, 26, 9) | -1.85 (Hist 0.42) | Oscillator | Buy |
| Average Directional Index (14) | 27.88 (+DI 20.9 / -DI 23.1) | Trend | Strong Sell |
| EMA 20 | 37.89 | MA | Buy |
| SMA 20 | 37.41 | MA | Buy |
| EMA 50 | 40.78 | MA | Strong Sell |
| SMA 50 | 43.25 | MA | Strong Sell |
| SMA 200 | 39.25 | MA | Strong Sell |
FY2025 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 2, 26 | Tyndall Joseph A. | director | S-Sale | 3,500 @ $49.70 | $173.9K |
| Aug 10, 26 |
| Began Marc A |
| officer: EVP & General Counsel |
| M-Exempt |
| 67,500 @ $8.16 |
| $550.8K |
| Aug 10, 26 | Began Marc A | officer: EVP & General Counsel | S-Sale | 67,500 @ $47.35 | $3.20M |
| Aug 10, 26 | Began Marc A | officer: EVP & General Counsel | M-Exempt | 67,500 @ $8.16 | $550.8K |
| Aug 11, 26 | Wendell Amy Mcbride | director | M-Exempt | 13,353 @ $14.85 | $198.3K |
| Aug 11, 26 | Wendell Amy Mcbride | director | S-Sale | 13,353 @ $48.42 | $646.6K |
| Aug 11, 26 | Wendell Amy Mcbride | director | M-Exempt | 13,353 @ $14.85 | $198.3K |
| Aug 7, 26 | Weiler Kathy Johnson | director | S-Sale | 14,150 @ $45.30 | $641.0K |
TTM vs. 5-year historical average (annual ratios)
| Metric | AXGN | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -56.4x | -42.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 83.6x | EPS est. 0.46 | Discount |
| Price / Book | 7.9x | 5.9x | Elevated |
| Price / Sales | 8.9x | 3.7x | Elevated |
| EV / EBITDA | -172.6x | 1615.8x | Discount |
| Return on equity | -17.9% | — | Weak |
| Gross margin | 74.6% | 77.4% | In line |
| Debt / Equity | 0.08 | 0.64 | Conservative |
| Piotroski / Altman Z | 4/9 | Z 27.32 | Safe zone |
Discounted cash flow model
Stock news · updated daily
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or AxoGen (AXGN). But which of these two stocks offers value investors a better bang for their buck right now?
ALACHUA, Fla. and TAMPA, Fla.
The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
/PRNewswire/ -- Stock Preachers News Commentary - Big technology names pulled the Nasdaq Composite to a weekly gain while the Dow Jones Industrial Average and
ALACHUA, Fla. and TAMPA, Fla.
On September 22, 2026, Axogen Inc (AXGN) shares fell by 3.0%, closing at $44.54. The stock is currently trading within a 52-week range of $15.27 to $52.91.
Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 29, 2026 | 0.12 | 0.12 | Miss -1.2% | $69.73M |
| Apr 28, 2026 | 0.12 | 0.07 | Miss -41.7% | $61.46M |
| Feb 24, 2026 | 0.09 | 0.07 | Miss -21.2% | $59.90M |
| Oct 29, 2025 | 0.09 | 0.12 | Beat 33.3% | $60.08M |
| Aug 5, 2025 | 0.06 | 0.12 | Beat 100.0% | $56.66M |
| May 8, 2025 | -0.01 | -0.02 | Miss -100.0% | $48.56M |
| 8-K | Sep 10, 2026 | 2026-09-10 06:02:31 | View |
| 4 | Sep 4, 2026 | 2026-09-04 16:08:06 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 16:33:52 | View |
| 4 | Aug 12, 2026 | 2026-08-12 16:13:23 | View |
| 4 | Aug 12, 2026 | 2026-08-12 16:12:49 | View |
| 4 | Aug 11, 2026 | 2026-08-11 16:15:35 | View |
Proxy statement (DEF 14A) disclosures